In this Healio Video Perspective from the ASRS annual meeting, Dilraj Grewal, MD, FASRS, discusses eyes that developed macular neovascularization in the GATHER trials.
The phase 3 GATHER1 and GATHER2 clinical trials examined the use of avacincaptad pegol in patients with geographic atrophy. Grewal said he and colleagues observed a slight increase in the incidence of macular neovascularization in patients treated with avacincaptad pegol (11.6%) vs. patients in the sham group (6.9%) in pooled data from both trials.
“Overall, our analysis found that development of macular neovascularization